Q32 Bio to present bempikibart trial data at EADV congress

Q32 Bio Inc. (Nasdaq: QTTB) announced it will present results from Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with severe or very severe alopecia areata at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, running September 30 through October 3, 2026.

The presentations will include additional 36-week results and initial findings from a 16-week off-drug period from the trial. Bempikibart is a fully human anti-IL-7Rα antibody designed to block IL-7 and TSLP signaling.

An oral presentation titled "Bempikibart, a novel IL-7Rα antibody, produces hair regrowth that persists off treatment in severe and very severe alopecia areata: efficacy and biomarker results from the Phase 2a SIGNAL-AA Part B trial" is scheduled for September 30, 2026, at 3:15 p.m. CEST in Hall A as part of the Late Breaking News session.

A poster presentation titled "Preliminary Results for an Open-label Phase 2a Trial (SIGNAL-AA Part B) of Bempikibart, a Novel IL-7Rα Antibody in Patients with Severe or Very Severe Alopecia Areata" will also be shown September 30 at 7:00 a.m. CEST in the Poster Area during the biologics, immunotherapy, and targeted therapy session.

Both presentations will be delivered by Arash Mostaghimi, MD, MPA, MPH, Associate Professor of Dermatology and Vice Chair of Clinical Trials and Innovation at Brigham and Women's Hospital and Harvard Medical School.

Jodie Morrison, Chief Executive Officer of Q32 Bio, said the presentations "underscores our commitment to bringing a differentiated, targeted therapeutic to patients with alopecia areata in need of new treatment options."

You May Also Be Interested In

• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
• AMTD Digital reports $1.2B in total assets, $42.4M profit
• Instacart (CART) Exploring Sale - The Information